Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Study Purpose
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Histologically proven diagnosis of GBM; gliosarcoma is also an eligible diagnosis.
- - The patient must consent to submission of tissue for central pathology review.
- - Patients who have already undergone central pathology review through their enrollment on another Radiation Therapy Oncology Group (RTOG) GBM trial do not need to consent to having their material re-reviewed by the central pathologist for this study.
- - All patients must consent to molecular analysis of pre-dasatinib tumor tissue.
- - Patients accrued to stage I (closed to accrual) or stage IB (opened to accrual May 5, 2009) must have tumors overexpressing at least 2 known dasatinib targets (i.e., SRC proto-oncogene, non-receptor tyrosine kinase [SRC], v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT], platelet-derived growth factor receptor [PDGFR], or ephrin type-A receptor 2 [EPHA2]) - Patients accrued to stage II (cohort closed; not currently applicable) do not require overexpression of SRC, KIT, PDGFR, or EPHA2.
- - History and physical examination, including height and weight, within 10 days prior to registration on study.
- - Brain magnetic resonance imaging (MRI) with and without gadolinium within 10 days prior to registration on study.
- - Contrast-enhanced computed tomography (CT) scans are allowed for patients who cannot undergo MRI scanning.
- - Karnofsky performance status >= 60.
- - Absolute neutrophil count (ANC) >= 1,000 cells/mm^3.
- - Platelets >= 75,000 cells/mm^3.
- - Hemoglobin (Hgb) >= 8.0 g/dl; (note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable) - Leukocytes >= 3,000 cells/mm^3.
- - Absolute lymphocyte count (ALC) >= 500 cells/mm^3.
- - Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 institutional upper limit of normal.
- - Creatinine =< 3 X institutional upper limit of normal or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
- - All patients must have undergone prior treatment with radiotherapy and temozolomide; no other prior treatments are allowed.
- - There must be unequivocal radiographic evidence for tumor progression by MRI or CT scan, and the same type of scan (i.e., MRI or CT) must be used throughout the period of protocol treatment for tumor measurement; patients must be on a stable or decreasing dose of corticosteroids for at least 5 days before the baseline MRI/CT is performed.
- - Patients having undergone recent surgery for recurrent/progressive disease are eligible as long as they have recovered from the effects of surgery; patients who recently underwent resection without measurable disease post-operatively are also eligible.
- - Measurable disease is not required for eligibility in patients who recently underwent resection as long as the following conditions are met as applicable: - Progression of disease led to the surgery.
- - Gliadel wafers were not placed during the most recent surgery.
- - Neither convection enhanced delivery nor catheters for infusion of chemotherapy were used during the most recent surgery.
- - Radioactive seeds were not placed during the most recent surgery.
- - The histology of the most recent surgery documented recurrent/persistent/progressive malignant glioma.
- - Women of childbearing potential must have a negative beta human chorionic gonadotropin (B HCG) pregnancy test =< 3 days prior to registration.
- - Patient must sign study-specific informed consent prior to study entry.
Exclusion Criteria:
- - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) - Radiotherapy within 4 weeks or temozolomide within 14 days prior to registration or failure to recover from adverse events of either radiotherapy or temozolomide.
- - Patients may not be receiving any other investigational agents.
- - Severe, active comorbidity, defined as follows: - Any clinically significant cardiovascular disease including the following: - Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months.
- - Transmural myocardial infarction or ventricular tachyarrhythmia within the past 6 months.
- - Prolonged corrected QT interval (QTc) > 480 msec (Fridericia correction) - Ejection fraction less than institutional normal.
- - Major conduction abnormality (unless a cardiac pacemaker is present) - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol.
- - Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; breastfeeding should be discontinued if the mother is treated with dasatinib.
- - History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib.
- - Patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible.
- - Patients must not be taking hepatic enzyme inducing antiepileptic drugs (EIAEDs); if patients were previously on EIAEDs that have been discontinued, patients must have been off EIAEDs for >= 2 weeks prior to initiation of dasatinib.
- - Patients who require antacids should use short-acting, locally active agents (e.g., Maalox, Mylanta etc.); however, these agents should not be taken within either 2 hours before or 2 hours after the dasatinib dose.
- - Use of antithrombotic and/or antiplatelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin, clopidogrel, ticlopidine, Aggrenox) - Use of ibuprofen or non-steroidal anti-inflammatory drugs (NSAIDs) - Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT00423735 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Andrew Lassman |
| Principal Investigator Affiliation | NRG Oncology |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH, Other |
| Overall Status | Completed |
| Countries | Canada, Saudi Arabia, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm |
PRIMARY OBJECTIVES:
- I. To determine the therapeutic efficacy of dasatinib in all patients (i.e., stages 1B and 2 combined) with recurrent/progressive glioblastoma (GBM) as measured by 6-month progression-free survival.
- I. To determine the therapeutic efficacy of dasatinib for stage 1B patients with recurrent/progressive GBM as measured by a hybrid endpoint of 6-month progression-free survival OR objective response of (complete response [CR] or partial response [PR]) rate.
- II. To determine patient overall survival.
- III. To determine the toxicity of dasatinib in the treatment of patients with GBM.
- IV. To determine radiographic response rate to treatment.
- V. To determine patient progression-free survival.
- VI. To explore molecular correlates of clinical outcome.
- VII. To explore pharmacokinetic correlates of dosing, toxicity, and efficacy.
Arms
Experimental: Treatment (dasatinib)
Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
Interventions
Drug: - Dasatinib
Given PO
Other: - Pharmacological Study
Correlative studies
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Mobile Infirmary Medical Center
Mobile, Alabama, 36607
Status
Address
Arizona Oncology Services Foundation
Scottsdale, Arizona, 85260
Status
Address
The University of Arizona Medical Center-University Campus
Tucson, Arizona, 85724
Status
Address
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Status
Address
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Status
Address
Mercy San Juan Medical Center
Carmichael, California, 95608
Status
Address
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Status
Address
Glendale Adventist Medical Center
Glendale, California, 91206
Status
Address
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Status
Address
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
Status
Address
Sutter Medical Center Sacramento
Sacramento, California, 95816
Status
Address
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
Status
Address
Mercy General Hospital Radiation Oncology Center
Sacramento, California, 95819
Status
Address
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California, 95687
Status
Address
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Status
Address
Beebe Medical Center
Lewes, Delaware, 19958
Status
Address
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Status
Address
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Status
Address
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Status
Address
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Status
Address
Integrated Community Oncology Network-Florida Cancer Center Beaches
Jacksonville Beach, Florida, 32250
Status
Address
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Status
Address
Integrated Community Oncology Network-Southside Cancer Center
Jacksonville, Florida, 32207
Status
Address
University of Florida Health Science Center - Jacksonville
Jacksonville, Florida, 32209
Status
Address
Baptist Medical Center South
Jacksonville, Florida, 32258
Status
Address
Jupiter Medical Center
Jupiter, Florida, 33458
Status
Address
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Status
Address
21st Century Oncology-Orange Park
Orange Park, Florida, 32073
Status
Address
21st Century Oncology-Palatka
Palatka, Florida, 32177
Status
Address
Bay Medical Center
Panama City, Florida, 32401
Status
Address
Integrated Community Oncology Network-Flager Cancer Center
Saint Augustine, Florida, 32086
Status
Address
John B Amos Cancer Center
Columbus, Georgia, 31904
Status
Address
Memorial Health University Medical Center
Savannah, Georgia, 31404
Status
Address
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Status
Address
Saint John's Hospital
Springfield, Illinois, 62702
Status
Address
Saint Vincent Anderson Regional Hospital/Cancer Center
Anderson, Indiana, 46016
Status
Address
Franciscan Saint Francis Health-Beech Grove
Beech Grove, Indiana, 46107
Status
Address
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
Status
Address
Reid Health
Richmond, Indiana, 47374
Status
Address
Menorah Medical Center
Overland Park, Kansas, 66209
Status
Address
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Status
Address
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Status
Address
Shawnee Mission Medical Center-KCCC
Shawnee Mission, Kansas, 66204
Status
Address
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Status
Address
Union Hospital of Cecil County
Elkton, Maryland, 21921
Status
Address
Boston Medical Center
Boston, Massachusetts, 02118
Status
Address
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Status
Address
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Status
Address
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Status
Address
Ascension Saint John Hospital
Detroit, Michigan, 48236
Status
Address
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Status
Address
Hurley Medical Center
Flint, Michigan, 48503
Status
Address
Genesys Regional Medical Center-West Flint Campus
Flint, Michigan, 48532
Status
Address
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Status
Address
Allegiance Health
Jackson, Michigan, 49201
Status
Address
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Status
Address
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Status
Address
Borgess Medical Center
Kalamazoo, Michigan, 49048
Status
Address
Sparrow Hospital
Lansing, Michigan, 48912
Status
Address
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Status
Address
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Status
Address
Lake Huron Medical Center
Port Huron, Michigan, 48060
Status
Address
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Status
Address
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Status
Address
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Status
Address
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Status
Address
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Status
Address
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital
Saint Paul, Minnesota, 55101
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Status
Address
Singing River Hospital
Pascagoula, Mississippi, 39581
Status
Address
Cape Radiation Oncology
Cape Girardeau, Missouri, 63703
Status
Address
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Status
Address
Truman Medical Center
Kansas City, Missouri, 64108
Status
Address
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Status
Address
Saint Joseph Health Center
Kansas City, Missouri, 64114
Status
Address
North Kansas City Hospital
Kansas City, Missouri, 64116
Status
Address
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Status
Address
Research Medical Center
Kansas City, Missouri, 64132
Status
Address
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Status
Address
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Status
Address
Heartland Regional Medical Center
Saint Joseph, Missouri, 64507
Status
Address
Washington University School of Medicine
Saint Louis, Missouri, 63110
Status
Address
Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri, 63376
Status
Address
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804
Status
Address
Mercy Hospital Springfield
Springfield, Missouri, 65804
Status
Address
CoxHealth South Hospital
Springfield, Missouri, 65807
Status
Address
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Status
Address
Renown Regional Medical Center
Reno, Nevada, 89502
Status
Address
Cheshire Medical Center-Dartmouth-Hitchcock Keene
Keene, New Hampshire, 03431
Status
Address
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Status
Address
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Status
Address
Virtua Memorial
Mount Holly, New Jersey, 08060
Status
Address
Sparta Cancer Treatment Center
Sparta, New Jersey, 07871
Status
Address
Virtua Voorhees
Voorhees, New Jersey, 08043
Status
Address
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Status
Address
Highland Hospital
Rochester, New York, 14620
Status
Address
University of Rochester
Rochester, New York, 14642
Status
Address
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Status
Address
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Status
Address
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Status
Address
Cleveland Clinic Akron General
Akron, Ohio, 44307
Status
Address
Summa Barberton Hospital
Barberton, Ohio, 44203
Status
Address
Aultman Health Foundation
Canton, Ohio, 44710
Status
Address
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, 45219
Status
Address
Grandview Hospital
Dayton, Ohio, 45405
Status
Address
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Status
Address
Miami Valley Hospital
Dayton, Ohio, 45409
Status
Address
Samaritan North Health Center
Dayton, Ohio, 45415
Status
Address
Veteran Affairs Medical Center
Dayton, Ohio, 45428
Status
Address
Blanchard Valley Hospital
Findlay, Ohio, 45840
Status
Address
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Address
Kettering Medical Center
Kettering, Ohio, 45429
Status
Address
UH Seidman Cancer Center at Salem Regional Medical Center
Salem, Ohio, 44460
Status
Address
Upper Valley Medical Center
Troy, Ohio, 45373
Status
Address
University Pointe
West Chester, Ohio, 45069
Status
Address
Cancer Treatment Center
Wooster, Ohio, 44691
Status
Address
Greene Memorial Hospital
Xenia, Ohio, 45385
Status
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Address
Salem Hospital
Salem, Oregon, 97301
Status
Address
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Status
Address
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Status
Address
Northeast Radiation Oncology Center
Dunmore, Pennsylvania, 18512
Status
Address
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Status
Address
Cherry Tree Cancer Center
Hanover, Pennsylvania, 17331
Status
Address
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Status
Address
Upper Delaware Valley Cancer Center
Milford, Pennsylvania, 18337
Status
Address
Reading Hospital
West Reading, Pennsylvania, 19611
Status
Address
WellSpan Health-York Hospital
York, Pennsylvania, 17403
Status
Address
AnMed Health Hospital
Anderson, South Carolina, 29621
Status
Address
Medical University of South Carolina
Charleston, South Carolina, 29425
Status
Address
Saint Francis Hospital
Greenville, South Carolina, 29601
Status
Address
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Status
Address
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Status
Address
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Status
Address
Thompson Cancer Survival Center - West
Knoxville, Tennessee, 37932
Status
Address
Thompson Cancer Survival Center at Methodist
Oak Ridge, Tennessee, 37830
Status
Address
University of Texas Medical Branch
Galveston, Texas, 77555-0565
Status
Address
M D Anderson Cancer Center
Houston, Texas, 77030
Status
Address
Covenant Medical Center-Lakeside
Lubbock, Texas, 79410
Status
Address
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Status
Address
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Status
Address
Logan Regional Hospital
Logan, Utah, 84321
Status
Address
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Status
Address
Intermountain Medical Center
Murray, Utah, 84107
Status
Address
McKay-Dee Hospital Center
Ogden, Utah, 84403
Status
Address
Utah Valley Regional Medical Center
Provo, Utah, 84604
Status
Address
Dixie Medical Center Regional Cancer Center
Saint George, Utah, 84770
Status
Address
Intermountain Health Care
Salt Lake City, Utah, 84103
Status
Address
Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah, 84106
Status
Address
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Status
Address
LDS Hospital
Salt Lake City, Utah, 84143
Status
Address
University of Vermont Medical Center
Burlington, Vermont, 05401
Status
Address
University of Vermont College of Medicine
Burlington, Vermont, 05405
Status
Address
Norris Cotton Cancer Center-North
Saint Johnsbury, Vermont, 05819
Status
Address
Southwest VA Regional Cancer Center
Norton, Virginia, 24273
Status
Address
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Status
Address
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Status
Address
Wheeling Hospital/Schiffler Cancer Center
Wheeling, West Virginia, 26003
Status
Address
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Status
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Address
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Status
Address
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Status
Address
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Status
Address
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Status
Address
Bay Area Medical Center
Marinette, Wisconsin, 54143
Status
Address
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Address
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
Status
Address
Green Bay Oncology - Oconto Falls
Oconto Falls, Wisconsin, 54154
Status
Address
Green Bay Oncology - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Status
Address
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
International Sites
Status
Address
London Regional Cancer Program
London, Ontario, N6A 4L6
Status
Address
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Quebec City, Quebec, G1R 2J6
Status
Address
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Status
Address
King Faisal Specialist Hospital and Research Centre
Riyadh, , 11211
